149 related articles for article (PubMed ID: 26211476)
21. Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.
Hoyne G; Rudnicka C; Sang QX; Roycik M; Howarth S; Leedman P; Schlaich M; Candy P; Matthews V
BMC Cancer; 2016 Feb; 16():151. PubMed ID: 26912236
[TBL] [Abstract][Full Text] [Related]
22. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
Yuan S; Lei S; Wu S
Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
[TBL] [Abstract][Full Text] [Related]
23. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
[TBL] [Abstract][Full Text] [Related]
24. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas.
Karan D; Lin FC; Bryan M; Ringel J; Moniaux N; Lin MF; Batra SK
Int J Oncol; 2003 Nov; 23(5):1365-71. PubMed ID: 14532978
[TBL] [Abstract][Full Text] [Related]
25. Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration.
Fry JL; Toker A
Cancer Res; 2010 Oct; 70(20):8187-98. PubMed ID: 20736367
[TBL] [Abstract][Full Text] [Related]
26. Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form.
Mongaret C; Alexandre J; Thomas-Schoemann A; Bermudez E; Chéreau C; Nicco C; Goldwasser F; Weill B; Batteux F; Lemare F
Int J Cancer; 2011 Aug; 129(4):791-8. PubMed ID: 21064090
[TBL] [Abstract][Full Text] [Related]
27. ADAM-15 disintegrin-like domain structure and function.
Lu D; Scully M; Kakkar V; Lu X
Toxins (Basel); 2010 Oct; 2(10):2411-27. PubMed ID: 22069559
[TBL] [Abstract][Full Text] [Related]
28. Recombinant disintegrin domain of ADAM15 inhibits the proliferation and migration of Bel-7402 cells.
Hou Y; Chu M; Du FF; Lei JY; Chen Y; Zhu RY; Gong XH; Ma X; Jin J
Biochem Biophys Res Commun; 2013 Jun; 435(4):640-5. PubMed ID: 23688428
[TBL] [Abstract][Full Text] [Related]
29. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9.
Hamada S; Satoh K; Fujibuchi W; Hirota M; Kanno A; Unno J; Masamune A; Kikuta K; Kume K; Shimosegawa T
Mol Cancer Res; 2012 Jan; 10(1):3-10. PubMed ID: 22064652
[TBL] [Abstract][Full Text] [Related]
30. Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy.
Moriwaki M; Le TT; Sung SY; Jotatsu Y; Yang Y; Hirata Y; Ishii A; Chiang YT; Chen KC; Shigemura K; Fujisawa M
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740916
[TBL] [Abstract][Full Text] [Related]
31. Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate Cancer.
Rubenstein CS; Gard JMC; Wang M; McGrath JE; Ingabire N; Hinton JP; Marr KD; Simpson SJ; Nagle RB; Miranti CK; Warfel NA; Garcia JGN; Arif-Tiwari H; Cress AE
Cancer Res; 2019 Sep; 79(18):4703-4714. PubMed ID: 31337652
[TBL] [Abstract][Full Text] [Related]
32. Platelet integrin
Mammadova-Bach E; Zigrino P; Brucker C; Bourdon C; Freund M; De Arcangelis A; Abrams SI; Orend G; Gachet C; Mangin PH
JCI Insight; 2016 Sep; 1(14):e88245. PubMed ID: 27699237
[TBL] [Abstract][Full Text] [Related]
33. The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression.
Lucas N; Day ML
J Cell Biochem; 2009 Apr; 106(6):967-74. PubMed ID: 19229865
[TBL] [Abstract][Full Text] [Related]
34. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
35. In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression.
Liu CM; Hsieh CL; He YC; Lo SJ; Liang JA; Hsieh TF; Josson S; Chung LW; Hung MC; Sung SY
PLoS One; 2013; 8(1):e53795. PubMed ID: 23342005
[TBL] [Abstract][Full Text] [Related]
36. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction.
Najy AJ; Day KC; Day ML
Cancer Res; 2008 Feb; 68(4):1092-9. PubMed ID: 18281484
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression.
Zhang J; Qin X; Sun Q; Guo H; Wu X; Xie F; Xu Q; Yan M; Liu J; Han Z; Chen W
Oncogene; 2015 Jun; 34(25):3283-95. PubMed ID: 25151965
[TBL] [Abstract][Full Text] [Related]
38. The disintegrin domain of ADAM17 antagonises fibroblast‑carcinoma cell interactions.
Trad A; Riese M; Shomali M; Hedeman N; Effenberger T; Grötzinger J; Lorenzen I
Int J Oncol; 2013 May; 42(5):1793-800. PubMed ID: 23545805
[TBL] [Abstract][Full Text] [Related]
39. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
[TBL] [Abstract][Full Text] [Related]
40. Amyloid precursor protein regulates migration and metalloproteinase gene expression in prostate cancer cells.
Miyazaki T; Ikeda K; Horie-Inoue K; Inoue S
Biochem Biophys Res Commun; 2014 Sep; 452(3):828-33. PubMed ID: 25218471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
